Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed su...
OPM's subsidiary passes EU QP audit
CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up
Zhitong A-share lock-up release overview | September 2
OPM: Expected net profit of approximately 37 million yuan in the first half of the year, a year-on-year increase of 53.28%
The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suit
OPM plans to issue shares to acquire 100% equity of Pengli Bio at a transaction price of 1.451 billion yuan